At CELLphenomics, we want to change the way new compounds enter the clinical phase of discovery. We recognize the need for more stratified approaches. CELLphenomics leverages its steady supply of fresh patient samples and automation to optimize drug sensitivity assays across a range of drug treatment classes.
Whether your focus is on chemotherapy, drug target identification , differentiating agents or cancer immunotherapy research, our expert team of scientists and engineers will work to “tune in” each assay for each specific drug class or even for a specific drug. We partner with Biotech and Pharma to help drive their preclinical drug development programs and to confidently transition their program into clinical development with patient stratification and biomarker development.
There is an ever-increasing array of cancer therapies. Together, we can make your compounds work.
- Targeted Therapy
- Epigenetic Modifiers
- Differentiating Agents
- Tumors of the nervous system
- Tumors of the GI
- Tumors of soft tissues including bone tumors